Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Astrimmune Ltd.
Some observers believe Indivior is paying a very reasonable price to get hold of OPNT003, an intranasal formulation of the opioid antagonist nalmefene, which is expected to be filed with the US FDA by the end of the year.
Chinese biotechs listed in the US have a watershed day, with many shares nosediving by over 10% amid leadership changes in China, where the retirement of several economic pragmatists appears to be adding to souring investment sentiment amid views on rising uncertainties and risks.
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.
Vespyr, incorporated in December 2021 after operating as Nurya when it acquired Cold-Eeze from Mylan in May that year, offers Defend-Eeze in lozenges containing echinacea, elderberry and vitamins C and D3 in addition to zinc.